Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amiflamine is a small molecule drug that acts as a selective and reversible inhibitor of monoamine oxidase A (MAO-A), with a preferential effect on serotonin (5-HT) catabolism. The active form is the (+)-enantiomer. Amiflamine also functions as a serotonin releasing agent and has some activity as an inhibitor of semicarbazide-sensitive amine oxidase (SSAO). It shows higher affinity for the serotonin transporter compared to norepinephrine and dopamine transporters, allowing it to selectively inhibit MAO-A in serotonergic neurons at low doses. At higher doses, this selectivity diminishes. Amiflamine is structurally related to phenethylamine and amphetamine classes[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amiflamine.